Masimo Corp. (MASI): New Study Shows Pronto Has Similar Accuracy to Commonly-Used Point-of-Care Hematology Analyzer

Masimo is a global leader in innovative, non-invasive monitoring technologies that significantly improve patient care, helping solve “unsolvable” problems. One of the company’s instruments, Pronto, measures hemoglobin.

The company announced today that a new study published in Postgraduate Medicine demonstrates non-invasive total hemoglobin measurements from the Pronto have an accuracy similar to those of the most commonly used invasive point-of-care hematology analyzer, HemoCue 201+ from Quest Diagnostics, in outpatient settings.

Total hemoglobin is one of the most frequently ordered laboratory tests in hospitals, urgent care centers, physician offices, and public health clinics. Anemia, which is low hemoglobin concentration, is among the most common blood disorders in the United States. It affects an estimated 3.4 million Americans, according to the National Center of Health Statistics.

The chief medical officer at Masimo, Dr. Michael O’Reilly, said, “The accuracy of the Pronto provides clinicians a powerful, yet painless, tool to test total hemoglobin without many of the risks associated with conventional, invasive testing.” This should help all healthcare providers improve patient care and outcomes.

For additional information about Masimo, the Pronto, and other products, please visit www.masimo.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html